Subscribe - Individual

Subscribe - Biotech Premium (Corporate)

Categories

blinklab_HJB
May 19th, 2024

Blinklab Partners with Autism Foundation for Pre-Registration Study

Blinklab (BB1: $0.382) which listed on the ASX last month at $0.20, may have easily gone down the VC funding route, with interest at the same time from the US venture capital sector.

 

Screenshot 20240523 105635
April 19th, 2024

IPO Preview – Blinklab

Company: Blinklab

Issue Price: $0.20

Funds to be raised: $7 million

ASX code: BB1

Lead Manager: Westar Capital (not underwritten)

Offer closes: 21 March 2024

Expected listing date: 4 April 2024

Market capitalisation on listing: $20 million

Screenshot 20240201 112927
January 4th, 2024

Top Six Picks for 2024 (Dimerix; ASX = DXB)

Dimerix - Interim Data Assessment in Mid-March

neuren p2 topline results
January 4th, 2024

Impressive Results from Neuren's NNZ-2591 Phase II Clinical Trial in Phelan- McDermid Syndrome

Last month, Neuren Pharmaceuticals (NEU; $24.65) announced impressive top-line data from its Phase II trial of NNZ-2591 conducted in 18 patients with Phelan-McDermid Syndrome (PMS).

CLINUVEL ONETIME USE
December 12th, 2023

Investor Interest Starts Return to Biotech Sector (Clinuvel)

Over the last two months, there have been some strong price movements in several major and minor biotech stocks. Following a downturn that has lasted almost two years, has the Australian sector finally bottomed?

We reviewed Clinuvel Pharmaceuticals, Dimerix, Imugene, and Neuren.

 

DIMERIX  ONETIME USE
December 12th, 2023

Investor Interest Starts Return to Biotech Sector (Dimerix)

Over the last two months, there have been some strong price movements in several major and minor biotech stocks. Following a downturn that has lasted almost two years, has the Australian sector finally bottomed?

We reviewed Clinuvel Pharmaceuticals, Dimerix, Imugene, and Neuren.

IMUGENE ONETIME USE
December 12th, 2023

Investor Interest Starts Return to Biotech Sector (Imugene)

Over the last two months, there have been some strong price movements in several major and minor biotech stocks. Following a downturn that has lasted almost two years, has the Australian sector finally bottomed?

We reviewed Clinuvel Pharmaceuticals, Dimerix, Imugene, and Neuren.

NEUREN ONETIME USE
December 12th, 2023

Investor Interest Starts Return to Biotech Sector (Neuren)

Over the last two months, there have been some strong price movements in several major and minor biotech stocks. Following a downturn that has lasted almost two years, has the Australian sector finally bottomed?

We reviewed Clinuvel Pharmaceuticals, Dimerix, Imugene, and Neuren.

phase23
November 20th, 2023

Neuren Completes First of Four Phase II Studies

In additional to the lucrative royalty stream and milestone payments Neuren Pharmaceuticals (NEU: $14.68) is receiving from its first drug DAYBUE, the company is also conducting four clinical studies in four separate neurodevelopmental disorders with its next drug candidate, NNZ-2591.

ad1
November 20th, 2023

Adalta Finalises Data for Licensing with Lead Compound AD214

Adalta (IAD: $0.018) is developing the next generation of therapeutic antibodies. These compounds are human protein drug candidates based on the unique structure of shark antibodies. This design combines the features of small molecule drugs (that can access binding sites conventionally difficult to access) and antibodies (which are characterized by the ability for highly specific binding).

CUV1
November 20th, 2023

Clinuvel Pharmaceuticals - Core Growth Focus Ahead

Clinuvel Pharmaceuticals (CUV: $16.62) has built a profitable business from the successful commercialization of Scenesse, a drug indicated for the treatment of EPP (erythropoietic protoporphyria). In the last financial year, revenue was up 19% and net profit was up 46% to $30.6 million. The company finished June with a cash balance of $157 million.

IMU1
November 20th, 2023

First Results for Imugene's Oncolytic Virus CF33

In May last year, Imugene (IMU: $0.089) commenced the first study with its novel oncolytic virus, CF33. CF33 was invented by Dr Yuman Fong and his team at City of Hope. It was in-licensed by Imugene in 2019 with the first clinical study having started in May last year.

CHM1
November 3rd, 2023

Chimeric Therapeutics - Four Phase Ib Studies in 2024 Ahead of Partnering Deals

For Chimeric Therapeutics (CHM: $0.029), achieving Phase Ib data from its programs is expected to position the company for licensing deals ahead of registration Phase II studies with CAR-T cell therapies.

AVR2
November 3rd, 2023

Anteris Technologies Secures $40 Million in Capital Raise to Prepare for Pivotal Study

Novel heart valve development company Anteris Technologies (AVR: $20.00) has secured commitments to raise $40 million at $20 per share through a private placement.

IMC_1
November 3rd, 2023

Immuron Achieves Record Travelan Sales in September Quarter

Immuron (IMC: $0.075) has reported a record $1.5 million in sales in the September quarter for its Travelan product used to prevent travelers' diarrhea.

ARX1
November 3rd, 2023

Aroa Biosurgery – On track for Revenue of NZ$72 - NZ$75 Million

Aroa Biosurgery (ARX: $0.79), a wound-healing products company, continues its resilient performance with a 35% increase in cash receipts during the September quarter compared to the PCP. Total revenue during the September quarter was NZ$14.8 million.

NEU1
November 3rd, 2023

Neuren Pharmaceuticals – Strong DAYBUE Sales in September Quarter at US$67 million

–3 November 2023–

Neuren  Pharmaceuticals' (NEU: $11.29) partner Acadia Pharmaceuticals has reported a strong second quarter of sales of its drug DAYBUE for Rett syndrome after having been launched in the US in April this year.

cogstate
October 10th, 2023

Acquisition Targets for Australian Biotech Sector (Cogstate)

Over the next 12-24 months a number of companies in the sector may receive acquisition bids. The last company to be acquired was ResApp Health for $180 million by Pfizer in 2022. Three companies viewed as potential targets by Bioshares are discussed below.

dmx1
October 10th, 2023

Major Validation Deal for Dimerix

Dimerix (DXB: $0.16) has signed a licensing deal for its lead compound, DMX-200, with Advanz Pharma. The deal gives Advanz rights to the use of DMX-200 for the treatment of FSGS (Focal Segmental Glomerulosclerosis) in Europe, the UK, Canada, Australia and New Zealand.

AVR1
October 3rd, 2023

Acquisition Targets for Australian Biotech Sector (Anteris Technologies)

Over the next 12-24 months a number of companies in the sector may receive acquisition bids. The last company to be acquired was ResApp Health for $180 million by Pfizer in 2022. Three companies viewed as potential targets by Bioshares are discussed below.

Pages